Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SAVEME

Financiado

Cerrado

A Modular Nanosystems Platform for Advanced Cancer Management Nano vehicles T...

A Modular Nanosystems Platform for Advanced Cancer Management Nano vehicles Tumor Targeting and Penetration Agents Molecular Imaging Degradome based Therapy SaveMe project will address current urgent needs for pancreatic cancer diagnosis and treatment by exploiting partners’ expertise and most recent research achievements for the design and development of novel modular nanosystems pla... ver más

28/02/2015

TAU

14M€

Presupuesto del proyecto: 14M€

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 17 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-02-28 No tenemos la información de la convocatoria

0% 76% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

17 Participantes

TAU

0.00€ | Lider

COLOROBBIA CONSULTING

N.D. | Participante

KU Leuven

N.D. | Participante

CIDETEC

N.D. | Participante

Proyectos interesantes

MCNANO

Nanotechnology

Medical Technol...

173K€ Cerrado

NanoMOFdeli

Nanotechnology

Medical Technol...

2M€ Cerrado

NANOTECHNOLOGYMETAST

Nanotechnology

Medical Technol...

100K€ Cerrado

NANO4TARMED

Nanotechnology

Medical Technol...

745K€ Cerrado

MAT2009-14734-C02-02

Nanotechnology

Medical Technol...

61K€ Cerrado

CTQ2014-54761-R

Nanotechnology

Medical Technol...

178K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

TEL AVIV UNIVERSITY No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 14M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto SaveMe project will address current urgent needs for pancreatic cancer diagnosis and treatment by exploiting partners’ expertise and most recent research achievements for the design and development of novel modular nanosystems platform integrating new functionalized nano-core particles and active agents. The modular platform will enable the design of diverse active nanosystems per diagnostic or therapeutic application as defined by their active agent compositions. For diagnostics, superior tracers will be developed for molecular MR/PET and gamma camera imaging, enabling efficient diagnosis and guided surgery respectively. Novel functionalized nano-core systems will be conjugated with semi-confluent active shell layer. Three types of shell layers will be design: (1) novel iron oxide nanoparticles as advanced MRI contrast agents and/or (2) DOTA complexes for MRI (with Gd3+), or PET (with Ga-68), or gamma camera (with Ga-69); (3) Integrating within one tracer both iron oxide nanoparticles and DOTA-Ga-68 complexes for a sequential or simultaneous MR/PET imaging. For therapeutics, active nanosystems will be developed to deliver (1) therapeutic siRNAs or (2) anti-MP-inhibitory-scFVs. These non-classic anti-tumor drugs will be designed based on an extensive tumor degradome analysis for combining blockage of selective matrix MPs, thus preventing basic invasive and metastasis steps, with siRNA based neutralization of secondary molecular effects induced by the specific protease inhibition. Individualized degradome analysis will be developed for potential profiling of anti-MP and siRNAs based therapy per patient. To facilitate the above diagnostics and therapeutic effects, advanced tumor targeting and penetration active agents will be linked to nano-core functionalized groups, including a biocompatible PEG layer linked to tumor selective MMP substrate molecules and highly safe and potent novel somatostatin analogue peptides targeting SSTR overexpression.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores